Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (30131)	1/12/2000 5:39:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Walter, I expect LGND's price to continue to rise because of increased institutional buying. With three approved products and profitability just around the corner, LGND is definitely coming onto the big boy's radar screen (and is apparently becoming a bigger target for some big boys who have already taken a position :-)). Can you give more details on Targretin on B-cell lymphomas, like NHL. I know ONTAK is in Phase II trials, but had not heard anything on Targretin and B-Cell lymphomas. As you know, the breast cancer update is really not new news.